Amwill Healthcare IPO: Key Investment Insights and Market Outlook

Amwill Healthcare Limited, a SME IPO, will close on February 7, 2025. Amwill Healthcare Limited was incorporated on August 10, 2017, and is headquartered in Bangalore, Karnataka. The company specializes in the development of derma-cosmetic products through collaborations with contract manufacturers and distributors.

Amwill Healthcare IPO Date

Here are the key dates related to the Amwill Healthcare IPO:

• IPO Opening Date: February 5, 2025
• IPO Closing Date: February 7, 2025
• Basis of Allotment Finalization: February 10, 2025
• Refunds Initiation: February 11, 2025
• Shares Credit to Demat Accounts: February 11, 2025
• Listing Date: February 12, 2025
• Listing on Exchange: BSE SME

These dates are crucial for investors interested in participating in the Amwill Healthcare IPO.

Amwill Healthcare IPO Details Issue Size

The total issue size of the Amwill Healthcare SME IPO is ₹59.98 crores. The issue comprises two components:

• Fresh Issue: 44,03,600 equity shares, aggregating up to ₹48.88 crores.
• Offer for Sale (OFS): 10,00,000 equity shares, aggregating up to ₹11.10 crores.

The face value of each equity share is ₹10, and the price band for the IPO is set between ₹105 to ₹111 per share.

Amwill Healthcare IPO Details: Proceeds Usage

The funds raised from the Amwill Healthcare SME IPO will be strategically allocated to support the company’s growth and operations:

Working Capital Requirements: ₹25 crores will be utilized to manage day-to-day business operations, ensuring smooth production and supply chain management.

Marketing & Brand Promotion: ₹5 crores will be invested in marketing campaigns and brand-building activities to enhance visibility and expand market reach.

General Corporate Purposes: The remaining funds will be used for business expansion, administrative expenses, and other corporate needs.

These allocations will strengthen Amwill Healthcare Limited’s financial position, enabling sustainable growth and operational efficiency.

Amwill Healthcare SME IPO Reservations

The Amwill Healthcare IPO has specific reservations for different categories of investors:

Qualified Institutional Buyers (QIB): Not more than 20% of the offer.
Retail Individual Investors (RII): Not less than 40% of the offer.
Non-Institutional Investors (NII): Not less than 40% of the offer.

This allocation strategy ensures a balanced distribution of shares among various investor groups.

Amwill Healthcare IPO Lot Size

The minimum lot size for the Amwill Healthcare IPO is 1,200 shares. Based on the upper end of the price band (₹111 per share), the minimum investment amount would be:

*This data is as per the 6 Feb 2025, Information may change in future.

Investors must apply for shares in multiples of the lot size.

Amwill Healthcare IPO: Promoter Shareholding

The Amwill Healthcare IPO shareholdings are Mr. Anand Gandhi and Mr. Tarun Gandhi. The shareholding pattern is as follows:

• Pre-IPO Promoter Shareholding: 97%
• Post-IPO Promoter Shareholding: Expected to decrease due to the dilution of equity through the IPO.

This change in shareholding structure is typical in public offerings as new investors acquire shares.

Amwill Healthcare Limited: Company Overview

Amwill Healthcare Limited is a leading derma-cosmetic company specializing in the development and distribution of high-quality skincare and dermatology products. Established in August 2017, the company is headquartered in Bangalore, Karnataka, and focuses on providing innovative and effective skincare solutions. Amwill Healthcare operates through a strong network of contract manufacturers and distributors, ensuring a seamless supply chain and high product standards.

The company’s product portfolio includes medicated skincare, anti-aging solutions, sun protection, and therapeutic creams, catering to dermatologists, skincare professionals, and consumers across India. With a commitment to research-driven innovation, Amwill Healthcare collaborates with leading pharmaceutical and cosmetic formulation experts to ensure its products meet global safety and efficacy standards.

Amwill Healthcare Limited has witnessed significant financial growth over the past few years. The company’s revenue, net worth, and profit margins have shown remarkable improvement, making it a promising investment opportunity. The company has focused on expanding its market reach, strengthening brand recognition, and introducing new products to drive long-term growth.

Amwill Healthcare Limited: Financial Performance

Understanding the financial performance of Amwill Healthcare Limited is crucial for potential investors. Below is a summary of the company’s financials:

Financial Performance Summary (₹ Cr)

Analysis:

• Strong Asset Growth: Total assets grew by 338.24%, indicating business expansion and financial stability.
• Revenue Increase: The company’s revenue surged by 84.16%, reflecting strong market demand and sales performance.
• Profitability Boost: Profit After Tax (PAT) increased by 153.69%, showcasing improved operational efficiency.
• High Net Worth Growth: Net worth soared by 1,489.93%, demonstrating significant value creation for shareholders.
• Reserves Expansion: Reserves & Surplus increased by 453.42%, indicating retained earnings and financial strength.

Amwill Healthcare Limited: Peer Analysis

Comparing Amwill Healthcare with its peers provides context to its performance. Below is a peer comparison based on key financial metrics:

Summary Analysis:

Earnings: Amwill Healthcare has significantly higher basic and diluted EPS compared to its peers.
Valuation: Amwill Healthcare’s P/E ratio is considerably lower than Vaishali Pharma and Trident Lifeline, suggesting potential undervaluation.

Amwill Healthcare IPO: Risk Factors

Investing in the Amwill Healthcare IPO involves certain risks that investors should carefully consider:

1. Dependence on Contract Manufacturers: The company relies on third-party manufacturers for production. Any disruption in their supply chain may impact product availability and quality.
2. Limited Geographical Presence: Amwill Healthcare has a concentrated market presence, which could restrict its expansion and expose it to region-specific economic fluctuations.
3. Competitive Market: The derma-cosmetic industry is highly competitive, with both established brands and new entrants posing a challenge to market share and profitability.
4. Regulatory Compliance Risks: The company operates in a highly regulated sector. Non-compliance with government policies and health regulations could lead to penalties or operational disruptions.
5. Fluctuating Raw Material Prices: Rising costs of active pharmaceutical ingredients (APIs) and other raw materials could impact profit margins.
6. IPO Market Sentiment: Stock market conditions and investor demand will determine the IPO’s success, which may not guarantee high post-listing performance.

Amwill Healthcare IPO Details: Contact Information

For any queries related to the Amwill Healthcare IPO, investors can reach out to the company’s registered office at:

Registered Office & Contact Details

Address:
No. 90, 4th Floor, 2nd Main, 7th Cross,
Chamrajpet, Bangalore – 560018, Karnataka, India.

Phone: +91 802 660 5825
Email: amwill@amwillhealthcare.com
Websites: www.amwillhealthcare.com

For all the insights on Amwill Healthcare IPO and detailed expert advice, you can download the SMC ACE App or visit the SMC Telegram Channels.

FAQs
1. What is the Amwill Healthcare IPO price band?

The Amwill Healthcare IPO price band is set between ₹105 to ₹111 per share. Investors must apply for shares within this price range.

2. When will the Amwill Healthcare IPO be listed on the stock exchange?

The IPO is expected to be listed on February 12, 2025, on the BSE SME platform.

3. What is the minimum lot size for the Amwill Healthcare IPO?

The minimum lot size for retail investors is 1,200 shares, requiring a minimum investment of ₹1,33,200 (at the upper price band of ₹111).

Reference:
https://www.bseindia.com/downloads/ipo/Amwill%20RHP_040220251653.pdf

Author: All Content is verified by SMC Global Securities.